Authors
Latest:
Current and Emergent Therapies for Systemic MastocytosisThe field of mastocytosis is witnessing a paradigm shift with precision medicine in the form of mutant KIT inhibitors.
Latest:
CAR T-Cell Use Generates Hope in Solid TumorsSteven M. Albelda, MD, discusses what he expects the future of chimeric antigen receptor T-cell use in solid tumors to look like.
Latest:
Treatments Differ in Rare Versus More Common Kidney CancersPavlos Msaouel, MD, PhD, discusses how the treatments and outcomes differ between patients with the rarer disease of renal medullary carcinoma than the more common renal cell carcinoma.
Latest:
Incorporating Biomarker Testing in Community Cancer Clinics: A Real-World Pilot StudyAlthough there is tremendous excitement about boundaries of science stretching beyond human imagination, realizing the real-world impact of scientific advancement on the health outcomes of patients provides a reality check on how far we still must go.
Latest:
Exploring Underrepresentation in Clinical Trials of Prostate CancerSmruthy Sivakumar, PhD, discusses a large-scale analysis of comprehensive genomic profiling utilization and ancestral characterization of the genomic landscape in patients with advanced prostate cancer.
Latest:
Emerging Options For Patients With Blood Cancers in Need of HSCTMitchell E. Horwitz, MD, discusses the next steps for research following the FDA approval of omidubicel.
Latest:
Darolutamide Combined with ADT Prior to RP Demonstrates Safety and Efficacy in Prostate CancerRegarding safety, the investigators did not observe any grade 3 or 4 adverse events during the study.
Latest:
Trastuzumab Deruxtecan Demonstrates Efficacy for mCRC in DESTINY-CRC01Salvatore Siena, MD, discusses the efficacy of the phase 2 DESTINY-CRC01 trial of trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer who have progressed on 2 or more treatments in this setting.
Latest:
Favorable Safety Profile Seen With Sabizabulin in mCRPCMark Markowski, MD, PhD, discusses the results of a phase 1b/2 study examining treatment with sabizabulin in patients with metastatic castration-resistant prostate cancer.
Latest:
Improving Access to Bone Marrow Transplant and Cellular TherapiesStem cell treatments offer hope for a variety of conditions. However, access to these potentially life-altering procedures is often hampered by social factors such as socioeconomic status, race, cultural background, and geographic location.
Latest:
Phase 3 NATALEE Study Assesses Ribociclib Plus ET in Early Breast CancerDennis J. Slamon, MD, discusses the rationale of the phase 3 NATALEE trial and ribociclib for the treatment of patients with HR+/HER2- early breast cancer.
Latest:
Closing Reflections on Evolving Practices for Bispecific AdministrationBrooke Peters, PharmD, BCOP, offers a closing reflection on the transition from inpatient to outpatient treatment of bispecific antibodies.
Latest:
Exploring the Key Takeaways from the CARTITUDE-2 Trial in Multiple MyelomaMounzer Agha, MD, discusses the phase 2 CARTITUDE-2 trial looking at ciltacabtagene autoleucel in patients with multiple myeloma.
Latest:
CHRYSALIS Study Shows Potential of Amivantamab/Lazertinib in EGFRm NSCLCSe-Hoon Lee, MD, an oncologist at the Samsung Medical Center in Seoul, Korea, discusses his focus of research in the lung cancer space, including the phase 1 CHRYSALIS study of amivantamab and lazertinib in patients with EGFR-mutated non–small cell lung cancer.
Latest:
Precision Medicine Implemented in the Community Oncology SettingTechnology plays a pivotal role in enhancing precision medicine within cancer care.
Latest:
COVID-19 and Its Impact on Oncology Clinical TrialsCoronavirus disease 2019 has disrupted oncologic care across the spectrum of cancer screening, diagnosis, and management.
Latest:
Breast Cancer Awareness Month: Recent Developments and Future Directions for Immunotherapy TreatmentMargaret E. Gatti-Mays, MD, MPH, FACP, evaluates the evolution of immunotherapy in cases of breast cancer for Breast Cancer Awareness Month.
Latest:
Choosing BTK Inhibitors Versus Venetoclax as First-Line CLL TherapyNilanjan Ghosh, MD, PhD, discusses when a Bruton’s tyrosine kinase inhibitor would be preferred over a BCL-2 inhibitor as first-line therapy for patients with chronic lymphocytic leukemia.
Latest:
JAVELIN HEAD AND NECK 100 Informs Future Trials in HNSCCThe potential benefit of avelumab in the subgroup of patients with high PD-L1 expression in JAVELIN HEAD AND NECK 100 provides a basis for further investigation and suggests a potential role for immune checkpoint inhibitors for locally advanced HNSCC.
Latest:
Making Treatment and Screening Decisions for Patients With Prostate CancerHagen F. Kennecke, MD, MHA, FRCP, medical oncologist, medical director of the Virginia Mason Cancer Institute and current chair of the NCI Rectal-Anal Cancer Task Force, discusses the treatment and screening decision making process for patients with prostate cancer.
Latest:
Developments in Targeted Therapies and Liquid BiopsiesDavid L. Bartlett, MD, discusses some of the most recent developments that have been seen in genomic testing for patients with cancer in recent years.
Latest:
Tisa-Cel Shows Efficacy and Durability in R/R Follicular LymphomaStephen Schuster, MD, discusses findings from follow-up of the phase 2 ELARA study presented at the 2023 ASH Annual Meeting.
Latest:
Larotrectinib Does Not Increase Risk of Fractures for Thyroid CancerTheodore W. Laetsch, MD, discusses various trials examining larotrectinib in patients with TRK fusion positive thyroid cancer.
Latest:
Understanding ADC Mechanism of Action Enhances Personalized Medicine in NSCLCThere is currently 1 FDA-approved antibody-drug conjugate available for patients with non-small cell lung cancer, and several more potentially coming down the pike.
Latest:
Rise in Prostate Cancer Cases Contributes to Challenges in CareMurugesan Manoharan, MD, FRACS, offers observations about prostate cancer care at Miami Cancer Institute.
Latest:
Exploring Preliminary Results of Ibrutinib and Fludarabine in CLLChristopher Pleyer, MD, discusses the phase 2 study of ibrutinib and short-course fludarabine in previously untreated patients with chronic lymphocytic leukemia.
